ライフサイエンスコーパス: nonalcoholic fatty liver

1 R = 0.89, 95% CI 0.83-0.97; P = 0.01), and a nonalcoholic fatty liver activity score >/=5 (OR = 0.08,

2 e aminotransferase normalization, age, and a nonalcoholic fatty liver activity score >/=5 may be usef

3 ing and feeding contributes to steatosis and nonalcoholic fatty liver and obesity.

4 Alcoholic and nonalcoholic fatty liver disease (ALD and NAFLD) are the

5 Twenty-six of the 120 subjects (21.7%) had nonalcoholic fatty liver disease (defined as MRI-PDFF >/

6 tegorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according to th

7 42926 C/T) variant on blood lipid traits and nonalcoholic fatty liver disease (NAFLD) across differen

8 ivers were assessed histologically using the nonalcoholic fatty liver disease (NAFLD) activity score

9 rth America, included subjects with NASH and nonalcoholic fatty liver disease (NAFLD) activity scores

10 Nonalcoholic fatty liver disease (NAFLD) alters drug res

11 Little is known about the prevalence of nonalcoholic fatty liver disease (NAFLD) among severely

12 Nonalcoholic fatty liver disease (NAFLD) and alcoholic l

13 essment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic l

14 ves many obesity-related diseases, including nonalcoholic fatty liver disease (NAFLD) and diabetes, a

15 167Lys) variant in genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) and disease sev

16 Nonalcoholic fatty liver disease (NAFLD) and heart failu

17 The incidence of nonalcoholic fatty liver disease (NAFLD) and hyperlipide

18 of saturated fat is a likely contributor to nonalcoholic fatty liver disease (NAFLD) and insulin res

19 lay an important role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progres

20 plore the role of liver aminotransferases in nonalcoholic fatty liver disease (NAFLD) and MetS.

21 L27RA), resembling the phenotype observed in nonalcoholic fatty liver disease (NAFLD) and nonalcoholi

22 Nonalcoholic fatty liver disease (NAFLD) and resulting n

23 The early stages of nonalcoholic fatty liver disease (NAFLD) are characteriz

24 Alcoholic fatty liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are common caus

25 Obstructive sleep apnea syndrome (OSAS) and nonalcoholic fatty liver disease (NAFLD) are frequently

26 rowing because obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) are replacing v

27 Patients with nonalcoholic fatty liver disease (NAFLD) are reported to

28 Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are significant

29 Inadvertent inclusion of subjects with nonalcoholic fatty liver disease (NAFLD) as controls can

30 epatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magne

31 Nonalcoholic fatty liver disease (NAFLD) can progress fr

32 Nonalcoholic fatty liver disease (NAFLD) comprises a spe

33 Nonalcoholic fatty liver disease (NAFLD) contributes to

34 ding on the liver transcriptome during early nonalcoholic fatty liver disease (NAFLD) development.

35 Nonalcoholic fatty liver disease (NAFLD) encompasses a r

36 Nonalcoholic fatty liver disease (NAFLD) encompasses a s

37 aging technique, are accurate for diagnosing nonalcoholic fatty liver disease (NAFLD) fibrosis.

38 Nonalcoholic fatty liver disease (NAFLD) has become a ma

39 Nonalcoholic fatty liver disease (NAFLD) has become high

40 Among these sequelae, nonalcoholic fatty liver disease (NAFLD) has become the

41 No treatment for nonalcoholic fatty liver disease (NAFLD) has been approv

42 An association between periodontitis and nonalcoholic fatty liver disease (NAFLD) has been report

43 The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased w

44 obesity, the IM composition of patients with nonalcoholic fatty liver disease (NAFLD) has not been we

45 Pediatric nonalcoholic fatty liver disease (NAFLD) histology demon

46 (PPP1R3B) that were strongly associated with nonalcoholic fatty liver disease (NAFLD) in adults of Eu

47 ients with type 2 diabetes (T2D) and reduces nonalcoholic fatty liver disease (NAFLD) in animal model

48 Nonalcoholic fatty liver disease (NAFLD) in non-obese pa

49 An independent role of nonalcoholic fatty liver disease (NAFLD) in the developm

50 V) as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offsprin

51 igh-fructose corn syrup (HFCS), and rates of nonalcoholic fatty liver disease (NAFLD) in the United S

52 The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty

53 The prevalence of nonalcoholic fatty liver disease (NAFLD) increases with

54 o analyzed the effects of obesity-associated nonalcoholic fatty liver disease (NAFLD) independent of

55 to segregate patients with well-compensated nonalcoholic fatty liver disease (NAFLD) into subpopulat

56 Nonalcoholic fatty liver disease (NAFLD) is a burgeoning

57 Nonalcoholic fatty liver disease (NAFLD) is a common liv

58 Nonalcoholic fatty liver disease (NAFLD) is a common pro

59 Nonalcoholic fatty liver disease (NAFLD) is a complex ch

60 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a consequenc

61 Nonalcoholic fatty liver disease (NAFLD) is a leading ca

62 Nonalcoholic fatty liver disease (NAFLD) is a leading ca

63 Nonalcoholic fatty liver disease (NAFLD) is a major caus

64 Nonalcoholic fatty liver disease (NAFLD) is a major caus

65 Importance: Nonalcoholic fatty liver disease (NAFLD) is a major chro

66 Nonalcoholic fatty liver disease (NAFLD) is a major fact

67 Nonalcoholic fatty liver disease (NAFLD) is a major worl

68 Nonalcoholic fatty liver disease (NAFLD) is a rapidly em

69 Nonalcoholic fatty liver disease (NAFLD) is a risk facto

70 Nonalcoholic fatty liver disease (NAFLD) is a significan

71 There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by

72 ection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important

73 Nonalcoholic fatty liver disease (NAFLD) is an increasin

74 Nonalcoholic fatty liver disease (NAFLD) is an obesity-r

75 Nonalcoholic fatty liver disease (NAFLD) is associated w

76 Nonalcoholic fatty liver disease (NAFLD) is associated w

77 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is associated w

78 Nonalcoholic fatty liver disease (NAFLD) is characterize

79 Nonalcoholic fatty liver disease (NAFLD) is characterize

80 Although nonalcoholic fatty liver disease (NAFLD) is closely link

81 oderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet

82 Although nonalcoholic fatty liver disease (NAFLD) is conventional

83 Nonalcoholic fatty liver disease (NAFLD) is highly preva

84 Nonalcoholic fatty liver disease (NAFLD) is increasingly

85 ver, the role of FOXOs in the development of nonalcoholic fatty liver disease (NAFLD) is not well und

86 Nonalcoholic fatty liver disease (NAFLD) is now the most

87 With no approved pharmacological treatment, nonalcoholic fatty liver disease (NAFLD) is now the most

88 Nonalcoholic fatty liver disease (NAFLD) is one of the m

89 Nonalcoholic fatty liver disease (NAFLD) is one of the m

90 Nonalcoholic fatty liver disease (NAFLD) is the hepatic

91 Nonalcoholic fatty liver disease (NAFLD) is the most com

92 Nonalcoholic fatty liver disease (NAFLD) is the most com

93 Nonalcoholic fatty liver disease (NAFLD) is the most com

94 Nonalcoholic fatty liver disease (NAFLD) is the most com

95 Nonalcoholic fatty liver disease (NAFLD) is the most com

96 Nonalcoholic fatty liver disease (NAFLD) is the most com

97 Nonalcoholic fatty liver disease (NAFLD) is the most com

98 Nonalcoholic fatty liver disease (NAFLD) is the most com

99 Nonalcoholic fatty liver disease (NAFLD) is the most com

100 Nonalcoholic fatty liver disease (NAFLD) is the most com

101 Nonalcoholic fatty liver disease (NAFLD) is the most com

102 Nonalcoholic fatty liver disease (NAFLD) is the most pre

103 Nonalcoholic fatty liver disease (NAFLD) is widespread i

104 e is ongoing debate on whether screening for nonalcoholic fatty liver disease (NAFLD) is worthwhile i

105 Nonalcoholic fatty liver disease (NAFLD) may increase th

106 Nonalcoholic fatty liver disease (NAFLD) may lead to hep

107 The origins of nonalcoholic fatty liver disease (NAFLD) may lie in earl

108 termine the influence of steatotic drugs and nonalcoholic fatty liver disease (NAFLD) on SHP expressi

109 model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is la

110 n developed in chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) patients.

111 inations and forms (alive or lyophilized) in nonalcoholic fatty liver disease (NAFLD) prevention.

112 c steatosis among HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV p

113 Nonalcoholic fatty liver disease (NAFLD) represents an e

114 Nonalcoholic fatty liver disease (NAFLD) represents the

115 Nonalcoholic fatty liver disease (NAFLD) spectrum disord

116 Nonalcoholic fatty liver disease (NAFLD) was the most co

117 ies have identified a cholestatic variant of nonalcoholic fatty liver disease (NAFLD) with portal inf

118 Nonalcoholic fatty liver disease (NAFLD), a common prelu

119 pathological polyploidization takes place in nonalcoholic fatty liver disease (NAFLD), a widespread h

120 e and insulin sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they

121 onsumption is associated with lower risk for nonalcoholic fatty liver disease (NAFLD), an obesity-rel

122 plays a relevant role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), and both risky

123 en suggested to be a key factor that induces nonalcoholic fatty liver disease (NAFLD), but the eviden

124 otein 3 (PNPLA3) is strongly associated with nonalcoholic fatty liver disease (NAFLD), but the mechan

125 ve been shown to contribute significantly to nonalcoholic fatty liver disease (NAFLD), data are prese

126 Nonalcoholic fatty liver disease (NAFLD), hepatic insuli

127 Most researchers focused on nonalcoholic fatty liver disease (NAFLD), in which incre

128 s (NASH), a clinically aggressive variant of nonalcoholic fatty liver disease (NAFLD), is becoming an

129 During nonalcoholic fatty liver disease (NAFLD), mitochondria a

130 PPARgamma activation may induce obesity and nonalcoholic fatty liver disease (NAFLD), one of the mos

131 atohepatitis (NASH), a more advanced form of nonalcoholic fatty liver disease (NAFLD), predisposes pa

132 Nonalcoholic fatty liver disease (NAFLD), the accumulati

133 Nonalcoholic fatty liver disease (NAFLD), the most commo

134 Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic op

135 Type 1 diabetes has been recently linked to nonalcoholic fatty liver disease (NAFLD), which is known

136 2 p.E167K, and GCKR p.P446L) associated with nonalcoholic fatty liver disease (NAFLD).

137 s of fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

138 n of LRH-1 SUMOylation to the development of nonalcoholic fatty liver disease (NAFLD).

139 ave emphasized the role of gut microbiota in nonalcoholic fatty liver disease (NAFLD).

140 atic steatosis in different murine models of nonalcoholic fatty liver disease (NAFLD).

141 s of fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

142 decreased in obesity, a key risk factor for nonalcoholic fatty liver disease (NAFLD).

143 oses to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD).

144 ALT]) are usually increased in patients with nonalcoholic fatty liver disease (NAFLD).

145 fibrosis, a major determinant of outcome in nonalcoholic fatty liver disease (NAFLD).

146 ebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD).

147 58 per 100,000 enrollees), driven by HCV and nonalcoholic fatty liver disease (NAFLD).

148 C) is increasingly reported in patients with nonalcoholic fatty liver disease (NAFLD).

149 specimens allows for grading and staging of nonalcoholic fatty liver disease (NAFLD).

150 nsulin resistance are highly associated with nonalcoholic fatty liver disease (NAFLD).

151 ted disorders, including type 2 diabetes and nonalcoholic fatty liver disease (NAFLD).

152 have been associated with the occurrence of nonalcoholic fatty liver disease (NAFLD).

153 ates with advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).

154 of de novo lipogenesis in the development of nonalcoholic fatty liver disease (NAFLD).

155 mic of obesity and insulin resistance favors nonalcoholic fatty liver disease (NAFLD).

156 y play a crucial role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).

157 er plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD).

158 e leading cause of death among patients with nonalcoholic fatty liver disease (NAFLD).

159 t may re-program liver for increased risk of nonalcoholic fatty liver disease (NAFLD).

160 the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD).

161 cohort of adult patients suspected of having nonalcoholic fatty liver disease (NAFLD).

162 of type 2 diabetes (T2D), and improvement of nonalcoholic fatty liver disease (NAFLD).

163 ls in the serum, is strongly associated with nonalcoholic fatty liver disease (NAFLD).

164 restimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

165 Despite this, little evidence of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic st

166 in AAs (BCAAs), are often found increased in nonalcoholic fatty liver disease (NAFLD); however, if th

167 fructose and other sugars has been linked to nonalcoholic fatty liver disease (NAFLD); however, the s

168 ffects of bariatric surgery in patients with nonalcoholic fatty liver disease (NASH) are not well est

169 evelop from metabolic liver disease, such as nonalcoholic fatty liver disease (NASH).

170 Nonalcoholic fatty liver disease (steatosis) is the most

171 10 mg/dL, RR = 1.68, 95% CI: 1.10-3.87), and nonalcoholic fatty liver disease (yes versus no, RR = 1.

172 e this, we enrolled 190 patients (32 without nonalcoholic fatty liver disease [NAFLD], 36 with simple

173 In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score >/=4 (n

174 steatohepatitis, 138 (47%) had reductions in nonalcoholic fatty liver disease activity score (NAS), a

175 evalence of fibrosis (P = 0.04) and a higher nonalcoholic fatty liver disease activity score (P = 0.0

176 ammation (r = 0.49, P = 2.35 x 10(-6) ), and nonalcoholic fatty liver disease activity score (r = 0.4

177 Although a decrease in the nonalcoholic fatty liver disease activity score could se

178 was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 his

179 leration in liver is not associated with the Nonalcoholic Fatty Liver Disease Activity Score or any o

180 an assays, steatosis graded according to the nonalcoholic fatty liver disease activity score, and nec

181 logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score.

182 ausal women with (1) histologic diagnosis of nonalcoholic fatty liver disease and (2) self-reported i

183 tion was undertaken in 17 men and women with nonalcoholic fatty liver disease and 15 body mass index

184 Diet-related health issues such as nonalcoholic fatty liver disease and cardiovascular diso

185 s in first-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis (NAFLD-ci

186 associated with liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this

187 -fat diet, the KO mice developed features of nonalcoholic fatty liver disease and had increased level

188 s in the United States are estimated to have nonalcoholic fatty liver disease and its potential morbi

189 Nonalcoholic fatty liver disease and its subtype nonalco

190 iant rs58542926 is a genetic risk factor for nonalcoholic fatty liver disease and progression to fibr

191 useful for understanding the pathogenesis of nonalcoholic fatty liver disease and type 2 diabetes, as

192 Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by ma

193 kely increase given the aging population and nonalcoholic fatty liver disease as a leading indication

194 the TM6SF2 gene is associated with pediatric nonalcoholic fatty liver disease but may confer protecti

195 nfers resistance to diet-induced obesity and nonalcoholic fatty liver disease by reducing food intake

196 expression was observed in a subset of human nonalcoholic fatty liver disease cases.

197 atio index (APRI), fibrosis-4 (FIB-4) score, nonalcoholic fatty liver disease fibrosis score (NFS), a

198 Nonalcoholic fatty liver disease has emerged as a novel

199 (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter settin

200 diabetes, extreme hypertriglyceridemia, and nonalcoholic fatty liver disease in both families.

201 cerides (IHTGs), and is the primary cause of nonalcoholic fatty liver disease in obese individuals.

202 Nonalcoholic fatty liver disease is a common consequence

203 Nonalcoholic fatty liver disease is associated with hepa

204 Nonalcoholic fatty liver disease is associated with meta

205 Nonalcoholic fatty liver disease is becoming the most co

206 Nonalcoholic fatty liver disease is increasing in preval

207 Nonalcoholic fatty liver disease is now acknowledged as

208 Nonalcoholic fatty liver disease is one of the most prev

209 Nonalcoholic fatty liver disease is seen as the hepatic

210 The cause of nonalcoholic fatty liver disease is the aberrant accumul

211 Nonalcoholic fatty liver disease is the most common caus

212 Nonalcoholic fatty liver disease is the most common live

213 in, glucose intolerance, insulin resistance, nonalcoholic fatty liver disease measures; and serum lev

214 nd increases in percentages of patients with nonalcoholic fatty liver disease or ALD.

215 wth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatoh

216 al of 51 NAFL patients, 30 NASH patients, 31 nonalcoholic fatty liver disease patients (without histo

217 e is associated with severity of fibrosis in nonalcoholic fatty liver disease patients of European an

218 ferase expression in a diet-induced model of nonalcoholic fatty liver disease reveals onset of hepati

219 ar after surgery (IQR, 2.5%-21.3%); the mean nonalcoholic fatty liver disease score was reduced from

220 ic steatohepatitis subtype within those with nonalcoholic fatty liver disease still requires liver bi

221 ease, type 2 diabetes mellitus, obesity, and nonalcoholic fatty liver disease through modulation of m

222 Nonalcoholic fatty liver disease was diagnosed in 68 pat

223 Incident nonalcoholic fatty liver disease was highest in patients

224 elevated fasting plasma glucose levels, and nonalcoholic fatty liver disease were also associated wi

225 er-related mortality in patients with NAFLD (nonalcoholic fatty liver disease) and AFLD (alcoholic fa

226 (obesity, metabolic syndrome, diabetes, and nonalcoholic fatty liver disease) have been associated w

227 s for which obesity is the direct cause (eg, nonalcoholic fatty liver disease) or is a significant ri

228 h poorly controlled type 2 diabetes and with nonalcoholic fatty liver disease, and a common variant o

229 ated with obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and cardiovascular dis

230 Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any eti

231 cal liver damage in alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C, but n

232 cyte death is associated with progression of nonalcoholic fatty liver disease, and inhibition of apop

233 s, insulin resistance and diabetes mellitus, nonalcoholic fatty liver disease, and obesity.

234 n obese and diabetic murine models and human nonalcoholic fatty liver disease, and thus it correlates

235 epatic steatosis, an important precursor for nonalcoholic fatty liver disease, are undefined.

236 abetes (T2D) and obesity are associated with nonalcoholic fatty liver disease, cardiomyopathy, and ca

237 ase, polyps, cancer, liver disease including nonalcoholic fatty liver disease, cirrhosis, hepatocellu

238 pe 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, a

239 In nonalcoholic fatty liver disease, Gal-9 is involved indi

240 In nonalcoholic fatty liver disease, hepatic gene expressio

241 In obese, insulin-resistant patients with nonalcoholic fatty liver disease, hepatic mIndy expressi

242 hird leading cause of death in patients with nonalcoholic fatty liver disease, is predicted to become

243 nd antibiotic-associated diarrhea, diabetes, nonalcoholic fatty liver disease, necrotizing enterocoli

244 y senescence were evaluated in patients with nonalcoholic fatty liver disease, nonalcoholic steatohep

245 bolic syndrome, impaired glucose metabolism, nonalcoholic fatty liver disease, obstructive sleep apno

246 CC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change

247 ding cause of fibrosis (viral hepatitis C vs nonalcoholic fatty liver disease, P = .025), inflammatio

248 soriasis may be more severe in patients with nonalcoholic fatty liver disease, particularly in those

249 upt intestinal homeostasis and contribute to nonalcoholic fatty liver disease, steatohepatitis, alcoh

250 In nonalcoholic fatty liver disease, the influence of sever

251 In patients with nonalcoholic fatty liver disease, the presence of severe

252 In patients with nonalcoholic fatty liver disease, we found no correlatio

253 induced intestinal dysbiosis is a driver for nonalcoholic fatty liver disease, we hypothesized that C

254 yte-specific ablation of Tnfaip3 exacerbated nonalcoholic fatty liver disease- and NASH-related pheno

255 The incidence of nonalcoholic fatty liver disease-related hepatocellular

256 ld liver fibrosis in pediatric patients with nonalcoholic fatty liver disease.

257 ibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.

258 s COP1 as a potential therapeutic target for nonalcoholic fatty liver disease.

259 and outcomes of alcoholic liver disease and nonalcoholic fatty liver disease.

260 pathogenesis of alcoholic liver disease and nonalcoholic fatty liver disease.

261 es mediate different aspects of both ALD and nonalcoholic fatty liver disease.

262 brosis severity in postmenopausal women with nonalcoholic fatty liver disease.

263 , while contrasting results were reported in nonalcoholic fatty liver disease.

264 eing considered as a target for treatment of nonalcoholic fatty liver disease.

265 s also been demonstrated in murine models of nonalcoholic fatty liver disease.

266 and hypertension, have been associated with nonalcoholic fatty liver disease.

267 ontent, mimicking the human condition termed nonalcoholic fatty liver disease.

268 lls in FASD Mthfr(+/-) mice, consistent with nonalcoholic fatty liver disease.

269 sis in a cohort of consecutive patients with nonalcoholic fatty liver disease.

270 related diseases such as type 2 diabetes and nonalcoholic fatty liver disease.

271 ysiological conditions and in the context of nonalcoholic fatty liver disease.

272 t ventricular (LV) function in subjects with nonalcoholic fatty liver disease.

273 h plasma triglyceride (TG) concentration and nonalcoholic fatty liver disease.

274 therapeutic potential in obese patients with nonalcoholic fatty liver disease.

275 nto the mechanisms of metabolic syndrome and nonalcoholic fatty liver disease.

276 eficiency protects mice from obesity-related nonalcoholic fatty liver disease.

277 ere has been an increase in the incidence of nonalcoholic fatty liver disease.

278 demia, impaired carbohydrate metabolism, and nonalcoholic fatty liver disease.

279 also typical hepatic manifestations such as nonalcoholic fatty liver disease.

280 ded new insights into metabolic syndrome and nonalcoholic fatty liver disease.

281 6.5 kg/m(2) ) with histologically confirmed nonalcoholic fatty liver disease.

282 f fetuin-A and diabetes can be attributed to nonalcoholic fatty liver disease.

283 but is now being overtaken by patients with nonalcoholic fatty liver disease.

284 reported high failure rates in patients with nonalcoholic fatty liver disease.

285 therapeutic applications in diseases such as nonalcoholic fatty liver disease.

286 ng of HIV infection include viral hepatitis, nonalcoholic fatty liver disease/nonalcoholic steatohepa

287 e (rs738409 C>G) is strongly associated with nonalcoholic fatty liver disease; to our knowledge, no d

288 The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from he

289 s), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic

290 tocyte Shp1 as a potential novel mediator of nonalcoholic fatty liver diseases in obesity.

291 r source of TG in the liver of patients with nonalcoholic fatty liver diseases.

292 d signaling as a new therapeutic approach to nonalcoholic fatty liver diseases.

293 Nonalcoholic fatty liver is associated with obesity-rela

294 It can be subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatoh

295 NASH is a potential outcome of nonalcoholic fatty liver (NAFL), a condition that occurs

296 from 61 consecutive patients diagnosed with nonalcoholic fatty liver (NAFL), nonalcoholic steatohepa

297 D) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatoh

298 nts transitioned between nine health states (nonalcoholic fatty liver, nonalcoholic steatohepatitis [

299 ogy for fibrosis stage (F0-F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis

300 ing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibr